Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 17/20 | 1.00 |
| ▸ | DRD2 | P14416 | 9/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.72 |
| ▸ | DRD5 | P21918 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | ADCY5 | O95622 | 2/20 | 0.72 |
| ▸ | ADCY6 | O43306 | 1/20 | 0.72 |
| ▸ | ADCY3 | O60266 | 1/20 | 0.72 |
| ▸ | ADCY9 | O60503 | 1/20 | 0.72 |
| ▸ | ADCY8 | P40145 | 1/20 | 0.72 |
| ▸ | ADCY7 | P51828 | 1/20 | 0.72 |
| ▸ | ADCY2 | Q08462 | 1/20 | 0.72 |
| ▸ | ADCY1 | Q08828 | 1/20 | 0.72 |
| ▸ | ADCY4 | Q8NFM4 | 1/20 | 0.72 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.72 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.72 |
| ▸ | THPO | P40225 | 1/20 | 0.72 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL11708014 | 0.99 | DRD1 (0.97) | DRD1DRD2KDM4EHPGDDRD5 | |
| Skf-38393 SCHEMBL29389401 | 0.84 | DRD1 (1.00) | DRD1DRD2KDM4EHPGDDRD5 | |
| Skf-38393 SCHEMBL469578 | 0.84 | DRD1 (1.00) | DRD1DRD2KDM4EHPGDDRD5 | |
| (R)-Skf-38393 SCHEMBL7941051 | 0.84 | DRD1 (1.00) | DRD1DRD2KDM4EHPGDDRD5 | |
| (R)-Skf-38393 SCHEMBL7201396 | 0.82 | DRD1 (1.00) | DRD1DRD2KDM4EHPGDDRD5 | |
| Skf-38393 SCHEMBL1874365 | 0.82 | DRD1 (1.00) | DRD1DRD2KDM4EHPGDDRD5 | |
| (R)-Skf-38393 SCHEMBL7201583 | 0.82 | DRD1 (1.00) | DRD1DRD2KDM4EHPGDDRD5 | |
| Skf-38393 SCHEMBL3425787 | 0.82 | DRD1 (1.00) | DRD1DRD2KDM4EHPGDDRD5 | |
| (R)-Skf-38393 SCHEMBL29634867 | 0.82 | DRD1 (1.00) | DRD1DRD2KDM4EHPGDDRD5 | |
| Skf-38393 SCHEMBL29387587 | 0.82 | DRD1 (1.00) | DRD1DRD2KDM4EHPGDDRD5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0005300-A1 | Substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, process for the preparation thereof, and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-11-14 | — | — | EP | claimed |
| EP-0005298-A1 | Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, process for the preparation thereof, and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-11-14 | — | — | EP | claimed |
| US-12594281-B2 | Pharmaceutical dosage forms and methods of use | EMALEX BIOSCIENCES, INC. (US) | 2026-04-07 | — | — | US | disclosed |
| US-20250288594-A1 | PHARMACEUTICAL DOSAGE FORMS AND METHODS OF USE | EMALEX BIOSCIENCES, INC. | 2025-09-18 | — | — | US | disclosed |
| EP-2872145-B1 | FUSED BENZAZEPINES FOR TREATMENT OF TOURETTE'S SYNDROME | EMALEX BIOSCIENCES INC (US) | 2022-03-09 | — | — | EP | disclosed |
| EP-3919060-A1 | ECOPIPAM FOR TREATMENT OF TOURETTES SYNDROME | Emalex Biosciences, Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| US-20210275540-A1 | TREATMENT OF TOURETTE'S SYNDROME WITH ECOPIPAM | EMALEX BIOSCIENCES INC (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3057595-B1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | EMALEX BIOSCIENCES INC (US) | 2020-04-29 | — | — | EP | disclosed |
| US-9949983-B2 | Fused benzazepines for treatment of stuttering | PSYADON PHARMACEUTICALS, INC. (US) | 2018-04-24 | — | — | US | disclosed |
| US-20160271141-A1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | Psyadon Pharmaceuticals ,Inc. | 2016-09-22 | — | — | US | disclosed |
| EP-3057595-A1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | Psyadon Pharmaceuticals, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| US-4284555-A | NEUROLEPTIC, ANTIDEPRESSANT, SEDATIVE | SCHERING CORPORATION (US) | 1981-08-18 | — | — | US | disclosed |
| US-4284556-A | 7,8-Amino, hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines | SMITHKLINE CORPORATION (US) | 1981-08-18 | — | — | US | disclosed |
| EP-0033632-A2 | 7,8-Amino, hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, process for their preparation and pharmaceutical compositions containing them | SMITHKLINE BECKMAN CORPORATION (US) | 1981-08-12 | — | — | EP | disclosed |
| EP-0005299-A1 | Substituted 1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, process for the preparation thereof, and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-11-14 | — | — | EP | disclosed |
| EP-0005298-A1 | Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, process for the preparation thereof, and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-11-14 | — | — | EP | disclosed |
| EP-0005298-A1 | Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, process for the preparation thereof, and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-11-14 | — | — | EP | disclosed |
| EP-0005298-A1 | Esters of substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, process for the preparation thereof, and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-11-14 | — | — | EP | disclosed |
| EP-0005300-A1 | Substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, process for the preparation thereof, and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-11-14 | — | — | EP | disclosed |
| EP-0005300-A1 | Substituted 8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines, process for the preparation thereof, and pharmaceutical compositions containing them | Technobiotic Ltd. (CH) | 1979-11-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12594281-B2 | Pharmaceutical dosage forms and methods of use | TAS2R5, TACR1, CHRM5 | DRD1 337/4885DRD2 270/4885KDM4E 4537/4885 |
| US-20250288594-A1 | PHARMACEUTICAL DOSAGE FORMS AND METHODS OF USE | MC2R, PTGDR, HTR5A | DRD1 81/4885DRD2 16/4885KDM4E 4578/4885 |
| US-20160271141-A1 | FUSED BENZAZEPINES FOR TREATMENT OF STUTTERING | TACR1, AVPR1A, AVPR1B | DRD1 28/4885DRD2 9/4885KDM4E 4194/4885 |
| US-20210275540-A1 | TREATMENT OF TOURETTE'S SYNDROME WITH ECOPIPAM | COMT, SLC6A3, HTR5A | DRD1 40/4885DRD2 14/4885KDM4E 4507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.